The British pharma is adding $500 million, and ADC production capabilities, to a planned Virginia facility. Elsewhere, ...

The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve ...

The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to ...

Bringing in a recruitment partner early gives sponsors the chance to test their protocols with real patients and gather ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...

In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing ...

The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...

A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...

George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new ...

The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for ...

Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the ...

The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically ...